33 Papers
303 Citations
E. Boucher is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Irinotecan & Hepatocellular carcinoma. The author has an hindex of 12, co-authored 33 publications.
Chat about Author
Papers
1398 brivanib versus placebo in patients with advanced hepatocellular carcinoma (hcc) who failed or were intolerant to sorafenib: results from the phase 3 brisk-ps study
Josep M. Llovet,Thomas Decaens,Jean-Luc Raoul,E. Boucher,Masatoshi Kudo,Charissa Chang,Y-K Kang,Eric Assenat,Ho Yeong Lim,Valérie Boige,Philippe Mathurin,Laetitia Fartoux,D.-Y. Lin,Jordi Bruix,Ronnie T.P. Poon,Morris Sherman,J.-F. Blanc,Richard S. Finn,Won Young Tak,Yee Chao,Rana Ezzeddine,D. Liu,Ian Walters,Joong-Won Park +23 more
106
Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
Pierre Michel,Antoine Adenis,F. Di Fiore,E. Boucher,M.P. Galais,Laetitia Dahan,Xavier Mirabel,H. Hamidou,Jean-Luc Raoul,J.H. Jacob,Marie-France Hellot,S Prod'Homme,Bernard Paillot +12 more
TL;DR: Cisplatin–irinotecan–radiotherapy is an active and well-tolerated regimen feasible in out-patients in patients with oesophageal cancer.
Cholestasis induces major histocompatibility complex class I expression in hepatocytes.
Yvon Calmus,Catherine Arvieux,Pierre Gane,E. Boucher,Bernard Nordlinger,Philippe Rouger,Raoul Poupon +6 more
TL;DR: The aim of this work was to assess the effect of cholestasis itself on hepatocyte MHC expression and to determine if immunosuppressive drugs might modulate this expression.
49
Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol.
Jean-Luc Raoul,M. Messner,E. Boucher,Jean-François Bretagne,Jean-Pierre Campion,Karim Boudjema +5 more
TL;DR: It is necessary to select patients suitable for surgery for hepatocellular carcinoma based on prior history and once they provide informed consent for surgery.
39
•Journal Article
131-iodine Lipiodol therapy in hepatocellular carcinoma.
TL;DR: Comparison with chemoembolization has shown similar results in terms of efficacy but with better tolerance for (131)I-lipiodol, and the use of another radionuclide, (188)Re, could probably improve the current method by reducing the need for radioprotection.
28